Personalized Cancer Vaccines Using mRNA Technology

Pancreatic cancer kills 88% of patients within 5 years. Six years after getting an experimental mRNA vaccine, nearly all of the responders in this trial are still alive. Brand new data drops Monday at American Association of Cancer Research, in San Diego. Vinod Balachandran MD and his team at Memorial Sloan Kettering Cancer Center will present 6-year follow-up from their Phase 1 trial of a personalized mRNA vaccine for pancreatic cancer. 16 patients with resected pancreatic cancer got a custom vaccine built from their own tumor. Each vaccine taught the immune system to recognize up to 20 mutations unique to that patient’s cancer. Half the patients mounted a strong immune response. The other half didn’t. Six years later, nearly all of the responders are still alive and cancer-free. For a disease where only about 1 in 8 patients typically survive 5 years, that’s a big deal. The new mechanistic piece: two types of immune cells appear to work as a team. Killer T cells attack the cancer while helper T cells keep the killers alive and fighting for years. That partnership looks like the reason the response is lasting so long. This is still a small trial of 16 people. A larger Phase 2 study sponsored by Genentech and BioNTech is enrolling now to see if the results hold up. For a cancer that’s resisted almost everything we’ve thrown at it, this is the most promising signal we’ve seen in a long time. #AACR26 #PancreaticCancer

Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes. It lacks the three receptors (ER/PR/HER2) that enable targeted therapies in other forms of breast cancer and recurs early (often peaking ~3 years after diagnosis). Its genomic instability and immunogenic microenvironment make it a strong candidate for individualized immunotherapy. In a Phase 1 clinical trial led by Prof. Dr. med. Marcus Schmidt and investigators from Germany and Sweden, just published in Nature, we evaluated an individualized neoantigen mRNA vaccine approach in 14 patients with early-stage TNBC after surgery and (neo)adjuvant therapy. Each vaccine encoded up to 20 patient-specific neoantigens on two mRNA molecules, delivered intravenously via lipid nanoparticles to target dendritic cells. The results showed robust immune responses: • All patients in the clinical trial developed vaccine-induced T cell responses against multiple neoantigens. • Vaccine-induced CD8⁺ T cells reached frequencies commonly achieved with adoptive T cell therapies and persisted functionally for years without boosters – evolving into both "ready-to-act" cytotoxic effector cells and stem-like memory T cells. • 11 of 14 patients remained relapse-free for up to six years post-vaccination. Furthermore, the findings in three patients with relapses were instructive for potential future combination treatment strategies to overcome resistance – each revealing a distinct escape mechanism to be addressed: • Enhancing response magnitude: The patient with the weakest vaccine-induced response relapsed but achieved complete remission on subsequent anti–PD-1, suggesting a response threshold and supporting combination strategies. • Targeting antigen-presentation loss: One patient showed near-complete loss of MHC class I (likely via B2M downregulation), despite vaccine-induced T cells being present, highlighting the need to address HLA-loss escape (e.g., antibodies or strategies restoring recognition). • Comprehensive tumor sequencing: In another patient the relapse originated from a contralateral, genetically independent tumor not covered by the vaccine design, underscoring the importance of sequencing multiple lesions in hereditary settings. Overall, these results demonstrate feasibility and durable neoantigen-specific immunity in TNBC supporting personalized mRNA cancer vaccines as platform technology, while pointing to novel treatment strategies to overcome resistance – especially through informed treatment combinations. 𝐋𝐢𝐧𝐤 𝐭𝐨 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧: https://lnkd.in/dk4fq6nA #CancerResearch #Oncology

BioNTech built 14 different cancer vaccines for 14 different patients. 11 are still cancer-free 6 years later. Each vaccine was designed from the patient's own tumour mutations. No two were alike. The target was triple-negative breast cancer, which is one of the most aggressive forms. The results were recently published in Nature. 🔬 The results are impressive: vaccine-induced killer T cells persisted for years without booster shots. In one patient, over 10% of circulating immune cells recognised a single tumour mutation, which is an extraordinary level of immune response. ⚠️ The three patients who relapsed revealed something equally important. Their tumours found escape routes, losing molecular markers, harbouring genetically distinct second tumours, or mounting too weak an immune response. 🧬 This entire approach runs on deep molecular profiling — sequencing, bioinformatics, and neoantigen prediction. At HQ Science, we're building on the same premise from the diagnostics side: whole-transcriptome sequencing captures molecular complexity that single-marker tests miss. Will personalised cancer vaccines become standard of care within a decade?

BioNTech SE recently launched Phase 1 trials for its mRNA lung cancer vaccine, one of ~70 clinical trials exploring using mRNA vaccines against cancer. Here’s a closer look at mRNA vaccines as a potential cancer therapy: The principle behind mRNA vaccines centers on identifying specific antigens within a patient's tumor, and crafting unique mRNA sequences for those antigens. When delivered, this instructs the patient's immune system to mount a response against the cancer. Recent clinical trials have showcased promising outcomes in patients, including those with types of cancers traditionally resistant to existing treatments – such as certain types of non-small cell lung cancer and aggressive melanomas. Although none have yet received regulatory approval, these vaccines have shown good tolerability and great potential for improving the immune system’s response to cancer. Leading the charge in this field are Moderna/Merck and BioNTech/Genentech, with promising mRNA cancer vaccine candidates in their pipelines. Moderna and Merck The collaboration between Moderna and Merck has yielded promising results, particularly with their mRNA-4157/V940 vaccine in combination with Keytruda for melanoma treatment. Phase 2 clinical trial results showed that this combination therapy led to a 49% lower risk of cancer recurrence or death compared to Keytruda treatment alone. mRNA-4157/V940 is now undergoing Phase 3 trials for melanoma with results expected in 2029, and is at the clinical trial stage for four additional cancer types. This underscores its versatility and potential for broad application across a wide range of cancers. Interestingly, Moderna’s close collaboration with Merck is highlighted by the fact that several of Moderna’s cancer-focused vaccines have 50-50 profit sharing with Merck. BioNTech BioNTech and Genentech are advancing cancer immunotherapy with their BNT122 vaccine. Phase 1 trials in pancreatic cancer patients showed that the vaccine induces lasting immune responses – up to 3 years post-administration – and is associated with extended recurrence-free survival. BNT122 is undergoing clinical trials for various cancers, with results from Phase 2 trials in pancreatic cancer expected in 2029, and Phase 2 trials in colorectal cancer in 2027. BioNTech currently has 11 mRNA vaccine candidates in its pipeline at the clinical trial stage for oncology indications. The company's ambitious roadmap includes launching a first wave of cancer immunotherapies by 2026, aiming for 10 approved cancer indications by 2030. The Future of mRNA Vaccines in Oncology With many highly anticipated trial results for mRNA vaccines as personalized cancer immunotherapies on the horizon, it will be intriguing to observe their effectiveness across different cancer types. Whether they are effective against a specific subset of cancers or a wide range of cancers, these early successes mark the beginning of a new era in cancer treatment.

A personalized mRNA cancer vaccine just slashed the risk of melanoma recurrence or death by nearly half in clinical trials. A pioneering clinical trial has revealed that pairing a personalized mRNA cancer vaccine with standard immunotherapy dramatically improves long-term outcomes for melanoma patients. Led by researchers at NYU Langone Health's Perlmutter Cancer Center, the Phase 2b trial—called KEYNOTE-942—evaluated the combination of the custom vaccine intismeran and the immunotherapy drug pembrolizumab (Keytruda). The historic five-year follow-up data, presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, showed that the combination therapy slashed the risk of recurrence or death by 49 percent compared to immunotherapy alone. This therapeutic strategy relies on intismeran, a tailored vaccine engineered using genetic data from a patient's individual tumor to stimulate a highly specific immune attack against cancer cells. After five years, nearly 69 percent of patients treated with the combination remained cancer-free, compared to just 49 percent of those who received only standard immunotherapy. Furthermore, the combination therapy reduced the risk of the cancer spreading to other parts of the body by 59 percent, proving that personalized vaccines could fundamentally transform how we treat aggressive cancers in the future. source: NYU Langone Health. (2026). Cancer Vaccine Sustains 49 Percent Melanoma Reduction After 5 Years. NYU Langone News.

Clinical trial results from BioNTech SE's individualized neoantigen #mRNA vaccine (using unmodified uridine and  liposomal nanoparticle formulation) in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy. In peripheral blood of nearly all patients, high-magnitude, vaccine-induced, mostly de novo T cell responses to multiple neoantigens were detected that remained functional for several years. Characterization of individual patients revealed that a large proportion of these T cells developed into two subsets: a late-differentiated phenotype with markers indicative of ‘ready-to-act’ cytotoxic effector T cells, and T cells with a stem cell-like memory phenotype. Eleven patients remained relapse-free for up to six years post-vaccination. Recurrence occurred in three patients: the individual with the weakest vaccine-induced T cell response relapsed, but achieved complete remission on subsequent anti-PD-1 therapy; another patient had a tumor with low major histocompatibility complex (MHC) class I expression with MHC class I-deficient cells growing out under vaccination; and the third patient was BRCA-positive and had a recurrence from a genetically distinct primary tumor. These findings demonstrate the feasibility of individualized RNA vaccines in TNBC, document persistence of vaccine-induced, functional neoantigen-specific T cells and provide insights into possible immune escape mechanisms that will guide future approaches. Link to paper https://lnkd.in/eE6iQrpH

This newsletter discusses a breakthrough in cancer immunotherapy - the successful use of personalized mRNA neoantigen vaccines in pancreatic cancer. Researchers have shown that the vaccine autologous gene cevumeran, combined with surgery, immunotherapy and chemotherapy, can induce long-lived and active CD8+ T cells for up to several years. These vaccine-induced T cells are able to delay or even prevent cancer recurrence. This innovation shows that cancer vaccines can not only produce strong and lasting immune responses, but also solve a key challenge in cancer vaccine development. The findings of this study mark an important milestone in precision oncology and may reshape the way we treat not only pancreatic cancer, but also other solid tumors. This is a big step forward in designing truly durable personalized immunotherapies. #CancerVaccine #PancreaticCancer #mRNAImmunotherapy #CD8TCells #PrecisionMedicine #ImmunoOncology #Neoantigen #PersonalizedMedicine #CancerResearch #BiotechInnovation #LongTermImmunity #TumorImmunology #NewsletterUpdate #MedicalBreakthroughs

A groundbreaking personalized mRNA cancer vaccine has shown remarkable promise in preventing pancreatic cancer from returning. In a small clinical trial, eight out of 16 patients mounted strong immune responses, and most of these responders remained cancer-free for over three years, a major improvement for a cancer with a five-year survival rate of only 13 percent. Unlike traditional vaccines that prevent infection, this cancer vaccine is administered after diagnosis and tumor removal. Scientists analyze each patient’s tumor to identify unique mutations and design an mRNA vaccine tailored to those cancer-specific markers. The vaccine then trains T cells, the immune system’s fighters, to recognize and destroy any lingering or returning cancer cells, acting as a personalized defense system within the body. Pancreatic cancer is one of the hardest cancers to treat because it is usually detected late and resists standard therapies. This new vaccine could provide long-term immune surveillance, preventing recurrence and potentially changing the outlook for patients worldwide. Although not every patient responded, the success proves that the immune system can indeed be taught to fight this deadly cancer. Source: Nature Medicine, Research Paper PMID: 39972124.

Triple-negative breast cancer (TNBC) is frequently associated with metastatic relapse, even at an early stage. Here we assessed an individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy. In peripheral blood of nearly all patients, high-magnitude, vaccine-induced, mostly de novo T cell responses to multiple neoantigens were detected that remained functional for several years. Characterization of individual patients revealed that a large proportion of these T cells developed into two subsets: a late-differentiated phenotype with markers indicative of ‘ready-to-act’ cytotoxic effector T cells, and T cells with a stem cell-like memory phenotype. Eleven patients remained relapse-free for up to six years post-vaccination. Recurrence occurred in three patients: the individual with the weakest vaccine-induced T cell response relapsed, but achieved complete remission on subsequent anti-PD-1 therapy; another patient had a tumour with low major histocompatibility complex (MHC) class I expression with MHC class I-deficient cells growing out under vaccination; and the third patient was BRCA-positive and had a recurrence from a genetically distinct primary tumour. These findings demonstrate the feasibility of individualized RNA vaccines in TNBC, document persistence of vaccine-induced, functional neoantigen-specific T cells and provide insights into possible immune escape mechanisms that will guide future approaches. Exciting new study results evaluating the efficacy of personalized neoantigen mRNA vaccines in patients with TNBC following surgical resection. Paper and research by Ugur Sahin and larger team at BioNTech SE